Akkermansia muciniphila and Heart Health: Proposed Roles in Lipid Metabolism, Atherosclerosis, and Blood Pressure

Akkermansia muciniphila is a gram-negative bacterium that colonizes the intestinal mucus layer and typically makes up more than 1% of a healthy adult gut microbiome. Over the past decade, researchers have moved from cataloguing its presence to asking a more pointed question: does its abundance meaningfully influence cardiovascular risk factors such as circulating lipids, arterial inflammation, and blood pressure? The honest answer is that the science is genuinely promising but still early, with most mechanistic evidence coming from cell studies and animal models, and human trials that are small and short.

What makes Akkermansia interesting from a heart-health standpoint is that it sits at the intersection of two systems that strongly influence cardiometabolic risk: the gut epithelial barrier and the host immune and metabolic signaling pathways. When the intestinal barrier is leaky, bacterial endotoxins such as lipopolysaccharide (LPS) can enter circulation and drive the kind of low-grade systemic inflammation that accelerates atherosclerosis. Akkermansia is proposed to reinforce that barrier, and its outer-membrane protein Amuc_1100 appears to engage immune receptors in ways that may dampen inflammatory signaling. This article walks through the proposed mechanisms and what limited human-level evidence currently exists, without overstating what is known.

The Gut Microbiome and Cardiovascular Risk: A Two-Way Street

The connection between gut bacteria and heart disease is no longer considered fringe biology. Researchers now recognize that the composition of the gut microbiome influences plasma lipids, blood pressure, systemic inflammation, and insulin sensitivity: all recognized cardiovascular risk factors. One illustration is a small observational study in which hypercholesterolemic patients treated with atorvastatin, one of the most widely prescribed cholesterol-lowering medications, had greater abundance of Akkermansia muciniphila and other bacteria than untreated patients; it is an association, not a causal test ^[1]. This raises an important question: do some of the cardiometabolic benefits attributed to statins operate partly through microbial pathways, and could optimizing those microbial communities independently benefit cardiovascular health?

Akkermansia muciniphila has been reported at lower abundance in some observational studies of people with prediabetes or type 2 diabetes, but a systematic review found the differences inconsistent across studies, and EFSA noted that such studies lacked a longitudinal design and may reflect reverse causation. These are conditions that elevate cardiovascular risk ^[4][5]. Whether reduced Akkermansia abundance is a cause, a consequence, or simply a marker of broader microbiome dysbiosis is still being untangled, but the mechanistic evidence reviewed below gives plausible biological reasons to study it more closely.

Proposed Mechanisms: How Akkermansia May Influence Lipid Metabolism

Akkermansia’s primary ecological niche is the mucus layer of the gut, where it degrades mucin glycoproteins and, in doing so, stimulates the host to replenish mucin production. This may sound unrelated to cholesterol, but the gut epithelium plays an active role in lipid absorption, bile acid recycling, and the secretion of gut hormones that regulate systemic metabolism. Bile acids, synthesized from cholesterol in the liver, are chemically transformed by gut bacteria during enterohepatic circulation, and the resulting bile acid profile affects how much cholesterol the liver draws from circulation.

Animal and cell-culture studies have proposed that Akkermansia abundance is linked to altered bile acid signaling and to the stimulation of glucagon-like peptide-1 (GLP-1) secretion from intestinal L-cells. GLP-1 receptors are expressed in the heart and vasculature, and GLP-1 receptor agonists, a class of diabetes medications, are now established to reduce major adverse cardiovascular events in clinical trials. Whether Akkermansia-driven GLP-1 stimulation reaches magnitudes relevant to cardiovascular protection in humans remains an open question that has not been established in large controlled trials.

The Amuc_1100 outer-membrane protein is the most-studied effector molecule from Akkermansia. In preclinical research, pasteurized (heat-treated) Akkermansia and isolated Amuc_1100 appear to activate Toll-like receptor 2 (TLR2) signaling in gut epithelial cells, improving tight-junction expression and reducing intestinal permeability. A less leaky gut means less circulating LPS, and lower endotoxemia is associated with reduced inflammatory activation of macrophages: the same cells that drive foam-cell formation in atherosclerotic plaques.

Pendulum Akkermansia Probiotic with Prebiotic Fiber, 90 Capsules

A single strain of live Akkermansia muciniphila at 100M AFU, with prebiotic fiber, in a delayed release capsule made with Pendulum’s anaerobic process. Third-party tested; one capsule a day with food, 90 capsules per bottle.

100M AFU90 count

Check Price on Amazon › As an Amazon Associate we earn from qualifying purchases.

Intestinal Barrier Integrity and Atherosclerosis

Atherosclerosis is fundamentally an inflammatory disease. Low-density lipoprotein (LDL) particles that become oxidized within arterial walls trigger macrophage infiltration, foam-cell accumulation, and the formation of unstable plaques that can rupture and cause myocardial infarction or stroke. Systemic inflammation amplifies this process at every stage, and the gut is a significant source of inflammatory signals when barrier function degrades.

Gut-derived LPS activates TLR4 on circulating monocytes and vascular endothelial cells, upregulating adhesion molecules and pro-inflammatory cytokines including TNF-α, IL-6, and IL-1β. Each of these cytokines is independently associated with increased cardiovascular risk in epidemiological research. The proposed model is that Akkermansia (by degrading mucin in a way that stimulates its renewal, upregulating tight-junction proteins like claudin-3 and occludin, and signaling through Amuc_1100) helps maintain the epithelial barrier against this LPS leak. This mechanism is biologically plausible and has been demonstrated in rodent models, but direct evidence of the full causal chain in humans is not yet established.

It is worth noting that the relationship between Akkermansia, gut permeability, and atherosclerotic progression has not been tested in a human cardiovascular outcomes trial. The mechanistic picture described here is built from preclinical data and inferences from observational associations. Researchers are actively working to close that gap.

The direct cardiovascular evidence comes from mice: oral A. muciniphila reversed Western diet-induced worsening of atherosclerotic lesions in Apoe-deficient mice without changing hypercholesterolemia. A review also warns that with a damaged gut barrier or a low-fiber diet, A. muciniphila can over-proliferate, accelerate mucus breakdown and exacerbate inflammation and disease progression ^[15][16][17].

Blood Pressure: Gut Bacteria, Short-Chain Fatty Acids, and Vascular Tone

Blood pressure regulation involves the kidneys, the renin-angiotensin-aldosterone system, vascular smooth muscle tone, and the autonomic nervous system. Recent research has added the gut microbiome to this picture. Gut bacteria ferment dietary fiber into short-chain fatty acids (SCFAs) (principally acetate, propionate, and butyrate) which interact with G-protein-coupled receptors (GPR41, GPR43) expressed in the vascular endothelium and kidney. SCFA-receptor signaling is associated with vasodilation and natriuresis (sodium excretion), both of which lower blood pressure.

Akkermansia is not itself a primary SCFA producer; it is a mucin degrader. However, the products of its mucin fermentation, including acetate, are proposed to be cross-fed to butyrate-producing bacteria in the colon; this has been described in mechanistic work and is not shown to change SCFA output or blood pressure in people. Additionally, by maintaining barrier integrity and reducing LPS-driven inflammation, Akkermansia may indirectly reduce the endothelial dysfunction and arterial stiffness that contribute to elevated systolic blood pressure. These are proposed mechanisms requiring further confirmation in humans.

What Human Evidence Currently Shows

Human evidence for Akkermansia and cardiovascular outcomes specifically is limited, and it is important to say that plainly. The most cited human supplementation studies have examined metabolic outcomes (body weight, insulin sensitivity, fasting glucose, and some lipid markers) rather than hard cardiovascular endpoints like myocardial infarction or stroke. One notable pilot trial in 40 overweight or obese insulin-resistant adults found that pasteurized Akkermansia muciniphila improved insulin sensitivity and lowered plasma total cholesterol versus placebo, while the live preparation did not significantly improve insulin sensitivity; the trial was small and short. A larger 2026 trial in adults with metabolic syndrome, using 30 billion pasteurized cells daily, did not meet its primary insulin sensitivity endpoint ^[5][6][2][3].

The study finding that atorvastatin-treated hypercholesterolemic patients had greater Akkermansia abundance than untreated patients ^[1] is an association in a small cohort, with no causal test. It is only loosely relevant here, and it does not show that microbial composition influences cardiovascular risk factors ^[1]. But ‘plausible’ and ‘proven’ are different standards, and the current evidence does not yet meet the bar of proof for a direct cardiovascular benefit of Akkermansia supplementation in humans.

Researchers are conducting larger and longer trials. Until those results are published and replicated, anyone considering Akkermansia supplementation for cardiovascular health should treat it as supporting a generally healthy gut environment rather than as a targeted cardiovascular therapy.

Dietary and Lifestyle Strategies That Support Akkermansia Abundance

Before reaching for a supplement, it is worth noting that Akkermansia abundance responds to diet. Polyphenols have raised Akkermansia mainly in mice: cranberry extract and green tea extract increased it, and a review states polyphenols may increase it. In people the picture is mixed, since a polyphenol-rich fermented black soybean product lowered LDL while Akkermansia abundance decreased in older adults. A systematic review found few diet trials measured Akkermansia, and inulin did not raise it in a pilot in adults with type 1 diabetes ^{[7][8][9][10][11][12]}.

Caloric restriction and time-restricted eating have also been linked to higher Akkermansia abundance, consistent with the observation that Akkermansia tends to be lower in obesity. Regular physical activity and avoiding prolonged antibiotic use are two additional factors associated with a healthier gut microbiome overall. These lifestyle approaches carry broad cardiovascular benefit regardless of their effects on any single bacterial species.

A Note on the Evidence

The evidence linking Akkermansia muciniphila to cardiovascular outcomes in humans is preliminary; most mechanistic data come from animal and cell models, and human trials to date have been small, short, and focused on metabolic rather than hard cardiovascular endpoints. Live Akkermansia probiotic formulations are not appropriate without physician guidance for immunocompromised individuals, people on immunosuppressive therapy, or those with active inflammatory bowel disease. This article is informational only and does not constitute medical advice.

300 Billion AFU Akkermansia Muciniphila – A Live Probiotics for Women and Men, Supports GL

The same 300 billion AFU delayed release format as the other high count options, 60 capsules for a 30 day supply. Worth noting its own label advises against use if you are elderly, pregnant, breastfeeding or under 18, which is stricter than most probiotic labelling.

300 Billion60 count

Check Price on Amazon › As an Amazon Associate we earn from qualifying purchases.

Frequently Asked Questions

Does Akkermansia muciniphila directly lower LDL cholesterol?

There is no established human trial demonstrating that Akkermansia supplementation directly lowers LDL cholesterol to a clinically meaningful degree. Proposed mechanisms, including altered bile acid recycling and reduced LPS-driven hepatic inflammation, could theoretically influence lipid metabolism, but these pathways have not been confirmed in adequately powered human studies. Research into the broader microbiome-lipid relationship, including findings that lipid-lowering medications like statins alter gut microbial composition ^[1], suggests the two systems interact, but this does not translate into a proven cholesterol-lowering effect for Akkermansia specifically.

Can Akkermansia help with blood pressure?

Akkermansia may indirectly support vascular health through mechanisms involving reduced intestinal permeability and the downstream effects of gut-derived short-chain fatty acids on vascular tone, but the only human report of a blood pressure effect is an abstract in resistant hypertension that gives no dose, form, sample size or control group, so it cannot be treated as evidence that supplementation lowers blood pressure. The proposed pathways are biologically plausible and are under active investigation. Anyone with hypertension should continue working with their physician on evidence-based treatment rather than relying on a probiotic supplement ^[13].

Is pasteurized Akkermansia safer than live Akkermansia?

Pasteurized (heat-killed) Akkermansia formulations have been used in human pilot trials and may carry a lower theoretical risk for immunocompromised individuals because the bacteria cannot replicate. In mice, the Amuc_1100 outer-membrane protein withstands pasteurization temperatures and partly recapitulates the bacterium’s benefits, but no human data show it drives the effect. Pasteurization does not eliminate all safety concerns: EFSA required the pasteurised ingredient’s viable count to be under 10 CFU/g because a possible adverse impact on gut barrier integrity in susceptible people could not be ruled out even at very low live-cell exposure. Both live and pasteurized formulations should be approached with caution by immunocompromised persons, those on immunosuppressive medications, and those with active inflammatory bowel disease ^[14][5].

How does gut permeability relate to atherosclerosis?

When the intestinal epithelial barrier is compromised, bacterial lipopolysaccharide (LPS) can translocate into circulation and activate inflammatory pathways in macrophages and vascular endothelial cells. This low-grade systemic inflammation promotes oxidized LDL uptake into arterial walls, foam-cell formation, and plaque development: the central process of atherosclerosis. Akkermansia is proposed to reduce this pathway by reinforcing tight junctions and stimulating mucin production, but the full causal chain has not been demonstrated in human cardiovascular studies.

What foods naturally support Akkermansia abundance?

Polyphenols such as cranberry extract and green tea extract have raised Akkermansia mainly in mice, and a review states polyphenols may increase it; in a trial in older adults, a polyphenol-rich fermented black soybean product lowered LDL while Akkermansia abundance decreased. A systematic review found few diet trials measured Akkermansia, and inulin did not raise it in a pilot in adults with type 1 diabetes. Higher abundance from diet has not been shown to improve cardiovascular health ^{[7][8][9][10][11][12]}.

Should I take an Akkermansia supplement for heart health instead of my prescribed medication?

No. Akkermansia supplements are not FDA-approved to treat, prevent, or cure any disease, including cardiovascular disease. Current evidence is early-stage and does not support replacing evidence-based cardiovascular therapies (such as statins, antihypertensives, or antiplatelet agents) with a probiotic supplement. Akkermansia research is promising as a possible complementary strategy to support gut and metabolic health, but any changes to prescribed cardiovascular medications should be made only in consultation with a qualified physician.

References

1. Khan TJ et al. Atorvastatin Treatment Modulates the Gut Microbiota of the Hypercholesterolemic Patients. Omics : a journal of integrative biology (2018). PMID 29432061
2. Liu Y et al. Pasteurized Akkermansia muciniphila as a candidate multi-effector pharmacological system in the gut-liver axis: evidence, unresolved causality, and translational priorities. Frontiers in pharmacology (2026). PMID 42846334
3. Suenaert P et al. Effect of pasteurized Akkermansia muciniphila MucT on insulin sensitivity, body composition, and GLP-1 production in subjects with metabolic syndrome: impact of low baseline gut Akkermansia levels. Gut microbes (2026). PMID 42343233
4. Letchumanan G et al. Gut Microbiota Composition in Prediabetes and Newly Diagnosed Type 2 Diabetes: A Systematic Review of Observational Studies. Frontiers in cellular and infection microbiology (2022). PMID 36046745
5. European Food Safety Authority (NDA Panel) Safety of pasteurised Akkermansia muciniphila as a novel food pursuant to Regulation (EU) 2015/2283. European Food Safety Authority (NDA Panel) (2021). source
6. Depommier C et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nature medicine (2019). PMID 31263284
7. Fernando F. Anhê et al. A polyphenol-rich cranberry extract protects from diet-induced obesity, insulin resistance and intestinal inflammation in association with increased Akkermansia spp. population in the gut microbiota of mice. Gut (2014). PMID 25080446
8. Gurley BJ et al. Decaffeinated Green Tea Extract Does Not Elicit Hepatotoxic Effects and Modulates the Gut Microbiome in Lean B6C3F₁ Mice. Nutrients (2019). PMID 30987244
9. Yuji Naito et al. A next-generation beneficial microbe: Akkermansia muciniphila. Journal of Clinical Biochemistry and Nutrition (2018). PMID 30087541
10. Chang SS et al. Plant-based polyphenol rich protein supplementation attenuated skeletal muscle loss and lowered the LDL level via gut microbiota remodeling in Taiwan's community-dwelling elderly. Food & function (2023). PMID 37795525
11. Sanne Verhoog et al. Dietary Factors and Modulation of Bacteria Strains of Akkermansia muciniphila and Faecalibacterium prausnitzii: A Systematic Review. Nutrients (2019). PMID 31336737
12. Ojetti V et al. Efficacy of inulin supplementation in metabolic control and Akkermansia muciniphila levels in subjects with type 1 diabetes: a pilot study. European review for medical and pharmacological sciences (2026). PMID 41636295
13. Yun F et al. Intermittent fasting ameliorates resistant hypertension through modulation of gut microbiota. Pharmacological research (2025). PMID 40701347
14. Plovier H et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nature medicine (2017). PMID 27892954
15. Jin Li et al. Akkermansia Muciniphila Protects Against Atherosclerosis by Preventing Metabolic Endotoxemia-Induced Inflammation in Apoe −/− Mice. Circulation (2016). PMID 27143680
16. Wu Q et al. Proline/serine-rich coiled-coil 1 alleviates atherosclerosis via remodeling tryptophan metabolism mediated by Akkermansia muciniphila. Experimental & molecular medicine (2026). PMID 41792233
17. Li S et al. Akkermansia muciniphila in cardiovascular diseases: opportunities and challenges. Frontiers in microbiology (2026). PMID 42422741
18. Jena PK et al. Intestinal Microbiota Contributes to the Development of Cardiovascular Inflammation and Vasculitis in Mice. Circulation research (2025). PMID 40026151

These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.